Answers are grounded in this paper and cite their sources.
Summary: Low volumetric retention limits the utility of fat grafting. Although inclusion of stem cells and platelet-rich plasma have been proposed to enhance graft retention, accumulating evidence has failed to show a clear benefit. Here, we propose a strategy to pharmacologically enhance stemness of stem and progenitor cell populations in fat grafts to promote increased volume retention and tissue health. We also propose how to integrate stemness-promoting and differentiation-promoting therapies such as platelet-rich plasma, and viability promoting therapies within the common fat grafting workflow to achieve optimal fat grafting results.
No takes yet. Share an insight, caveat, or question.
Izadpanah et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: